These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 12116821)

  • 21. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
    Schäfer A; Fraccarollo D; Eigenthaler M; Tas P; Firnschild A; Frantz S; Ertl G; Bauersachs J
    Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1071-7. PubMed ID: 15761193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function.
    Wassmann S; Faul A; Hennen B; Scheller B; Böhm M; Nickenig G
    Circ Res; 2003 Oct; 93(9):e98-103. PubMed ID: 14551237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pro- and antiangiogenic effects of statins.
    Skaletz-Rorowski A; Kureishi Y; Shiojima I; Walsh K
    Semin Vasc Med; 2004 Nov; 4(4):395-400. PubMed ID: 15861320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerivastatin potentiates nitric oxide release and enos expression through inhibition of isoprenoids synthesis.
    Kalinowski L; Dobrucki IT; Malinski T
    J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):585-95. PubMed ID: 12512694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of statins on endothelium and endothelial progenitor cell recruitment.
    Walter DH; Dimmeler S; Zeiher AM
    Semin Vasc Med; 2004 Nov; 4(4):385-93. PubMed ID: 15861319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats.
    Giusti-Paiva A; Martinez MR; Felix JV; da Rocha MJ; Carnio EC; Elias LL; Antunes-Rodrigues J
    Shock; 2004 Mar; 21(3):271-5. PubMed ID: 14770041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydroxy-methylglutaryl-coenzyme A reductase inhibition improves endothelial dysfunction in type-1 diabetes.
    Joyce M; Moore K; Thompson C; Fitzgerald P; Fennessy F; Kelly CJ; Bouchier-Hayes DJ
    Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):432-7. PubMed ID: 15015196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse balance of nitric oxide/peroxynitrite in the dysfunctional endothelium can be reversed by statins.
    Heeba G; Hassan MK; Khalifa M; Malinski T
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):391-8. PubMed ID: 18049306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HMG-CoA reductase inhibitors: Is the endothelium the main target?
    Puddu P; Puddu GM; Muscari A
    Cardiology; 2001; 95(1):9-13. PubMed ID: 11385185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lovastatin induces the expression of bradykinin type 2 receptors in cultured human coronary artery endothelial cells.
    Liesmaa I; Kokkonen JO; Kovanen PT; Lindstedt KA
    J Mol Cell Cardiol; 2007 Nov; 43(5):593-600. PubMed ID: 17900611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway.
    Hiraoka M; Nitta N; Nagai M; Shimokado K; Yoshida M
    Life Sci; 2004 Jul; 75(11):1333-41. PubMed ID: 15234191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia.
    Kumai T; Oonuma S; Matsumoto N; Takeba Y; Taniguchi R; Kamio K; Miyazu O; Koitabashi Y; Sekine S; Tadokoro M; Kobayashi S
    Life Sci; 2004 Mar; 74(17):2129-42. PubMed ID: 14969717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Bocan TM
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement of age-related endothelial dysfunction by simvastatin: effect on NO and COX pathways.
    de Sotomayor MA; Pérez-Guerrero C; Herrrera MD; Jimenez L; Marín R; Marhuenda E; Andriantsitohaina R
    Br J Pharmacol; 2005 Dec; 146(8):1130-8. PubMed ID: 16231003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects.
    Yamamoto E; Yamashita T; Tanaka T; Kataoka K; Tokutomi Y; Lai ZF; Dong YF; Matsuba S; Ogawa H; Kim-Mitsuyama S
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):556-63. PubMed ID: 17170375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New insights into the relationship between myocardial perfusion and lipid-lowering.
    Blumenthal RS; Gluckman TJ
    J Am Coll Cardiol; 2003 Aug; 42(4):611-3. PubMed ID: 12932589
    [No Abstract]   [Full Text] [Related]  

  • 37. Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide.
    McGown CC; Brookes ZL
    Br J Anaesth; 2007 Feb; 98(2):163-75. PubMed ID: 17251210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HMG-CoA reductase inhibitors: a new class of anti-inflammatory drugs?
    Rossen RD
    J Am Coll Cardiol; 1997 Nov; 30(5):1218-9. PubMed ID: 9350918
    [No Abstract]   [Full Text] [Related]  

  • 39. Molecular effects of HMG-CoA reductase inhibitors on smooth muscle cell proliferation.
    Skaletz-Rorowski A; Eschert H; Pawlus E; Breithardt G
    J Am Coll Cardiol; 2001 Jan; 37(1):337-8. PubMed ID: 11153768
    [No Abstract]   [Full Text] [Related]  

  • 40. Statins, skin, and the search for a test of endothelial function.
    Celermajer DS
    J Am Coll Cardiol; 2003 Jul; 42(1):78-80. PubMed ID: 12849663
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.